Atlas Trials

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

Clinical trial NCT05329051 · UNKNOWN

Trial details

NCT number
NCT05329051
Sponsor
Sinocelltech Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
SARS-CoV-2 InfectionCOVID-19
Start date
2022-07-01
Primary completion
2022-09-01
Enrollment
400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.